Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095238 · ClinicalTrials.gov registry record · Phase 3
Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,128
- Enrollment target
NCT00095238 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 4,128 participants.
The verdict
NCT00095238, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,128 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if Irbesartan is superior to placebo in reducing mortality and cardiovascular morbidity in subjects with heart failure with preserved systolic function. The safety of this treatment will also be studied.
Interventions
- DRUG Placebo
- DRUG Irbesartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,128 participants |
| Start Date | 2002-06 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095238
The ClinicalTrials.gov registry entry for NCT00095238 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00095238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095238 about?
NCT00095238 is a clinical study titled "Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)". The purpose of this clinical research study is to learn if Irbesartan is superior to placebo in reducing mortality and cardiovascular morbidity in subjects with heart failure with preserved systolic function. The safety of this treatment will also be studied.
What is the current status of trial NCT00095238?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,128 participants. The study started on 2002-06. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00095238?
The interventions under investigation include: Placebo (DRUG), Irbesartan (DRUG).
Who is sponsoring clinical trial NCT00095238?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.